Skip to main content
Erschienen in:

03.08.2020 | Original Article

Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals

verfasst von: Chinedu Ukaegbu, Zohar Levi, Tara D. Fehlmann, Hajime Uno, Anu Chittenden, Jennifer A. Inra, Shilpa Grover, Fay Kastrinos, Sapna Syngal, Matthew B. Yurgelun

Erschienen in: Familial Cancer | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Germline variants in the APC and MUTYH genes contribute to colorectal cancer (CRC) and adenoma risk, though may occur with varying frequencies in individuals of different ancestries. The aim of this study was to evaluate the prevalence of APC, monoallelic MUTYH and biallelic MUTYH germline variants in Ashkenazi Jewish (AJ) and Other Ancestry (OA) individuals with colorectal adenomas. We studied 7225 individuals with colorectal adenomas who had germline APC and MUTYH testing at a commercial laboratory. Cross-sectional medical history data were extracted from provider-completed test requisition forms. We performed bivariate analysis to compare the frequency of APC and MUTYH variants between AJ and OA, and examined APC p.I1307K and monoallelic MUTYH carrier phenotypes using logistic regression. Pathogenic APC variants occurred in 38/285 AJ (13%) and 1342/6940 OA (19%; P = 0.09); biallelic MUTYH variants in 2/285 (1%) AJ and 399/6940 (6%) OA (P < 0.0001); APC p.I1307K in 35/285 (12%) AJ and 29/6940 (1%) OA (P < 0.0001); and monoallelic MUTYH in 2/285 (1%) AJ and 133/6940 (2%) OA (P = 0.06). Monoallelic MUTYH variants were significantly associated with having a personal history of CRC, regardless of ancestry (OR 1.78; 95% CI 1.21–2.49; P < 0.01), but no significant association was found between APC p.I1307K variants and personal history of CRC (OR 1.38; 95% CI 0.79–2.44; P = 0.26). Ashkenazim with colorectal adenomas rarely have monoallelic or biallelic MUTYH variants, suggesting different genetic etiologies for polyposis in AJ compared to OA individuals. AJ ancestry assessment may be important in clinical evaluation for polyposis.

Literatur
  1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Colorectal (2019) National Comprehensive Cancer Network. https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​genetics_​colon.​pdf. Accessed 31 Jan 2020
  2. Yurgelun MB, Kulke MH, Fuchs CS, Allen BA, Uno H, Hornick JL, Ukaegbu CI, Brais LK, McNamara PG, Mayer RJ, Schrag D (2017) Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 35(10):1086View Article
  3. Win AK, Hopper JL, Jenkins MA (2011) Association between monoallelic MUTYH mutation and colorectal cancer risk: a meta-regression analysis. Fam Cancer 10(1):1–9View Article
  4. Laken SJ, Petersen GM, Gruber SB, Oddoux C, Ostrer H, Giardiello FM, Hamilton SR, Hampel H, Markowitz A, Klimstra D, Jhanwar S (1997) Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 17(1):79–83View Article
  5. Win AK, Dowty JG, Cleary SP, Kim H, Buchanan DD, Young JP, Clendenning M, Rosty C, MacInnis RJ, Giles GG, Boussioutas A (2014) Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology 146(5):1208–1211View Article
  6. Inra JA, Steyerberg EW, Grover S, McFarland A, Syngal S, Kastrinos F (2015) Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genet Med 17(10):815–821View Article
  7. Grover S, Kastrinos F, Steyerberg EW, Cook EF, Dewanwala A, Burbidge LA, Wenstrup RJ, Syngal S (2012) Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 308(5):485–492View Article
  8. Cox DM, Nelson KL, Clytone M, Collins DL (2018) Hereditary cancer screening: case reports and review of literature on ten Ashkenazi Jewish founder mutations. Mol Genet Genom Med 6(6):1236–1242View Article
  9. Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW, Kubik M, Landefeld CS, Mangione CM (2019) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA 322(7):652–665View Article
  10. Landon M, Ceulemans S, Saraiya DS, Strike B, Arnell C, Burbidge LA, Moyes K, Theisen A, Fernandes PH, Ji JQ, Abbott B (2015) Analysis of current testing practices for biallelic MUTYH mutations in MUTYH-associated polyposis. Clin Genet 87(4):3View Article
  11. Lejbkowicz F, Cohen I, Barnett-Griness O, Pinchev M, Poynter J, Gruber SB, Rennert G (2012) Common MUTYH mutations and colorectal cancer risk in multiethnic populations. Fam Cancer 11(3):329–335View Article
  12. Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM (2017) Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3(4):464–471View Article
  13. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, Timms K, Garber JE, Herold C, Ellisen L, Krejdovsky J (2015) Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next-generation sequencing with a 25-gene panel. Cancer 121(1):25–33View Article
  14. Heald B, Church J (2014) Genetic testing for hereditary colorectal cancer syndromes: a significant change in technology and its clinical implications. Colorectal Dis 16(12):942View Article
  15. Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, Edwards E, Evans DG, Maher ER, Vasen HF, Hes FJ (2009) Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 137(2):489–494View Article
  16. Boursi B, Sella T, Liberman E, Shapira S, David M, Kazanov D, Arber N, Kraus S (2013) The APC p I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer 49(17):3680–3685View Article
  17. Healio. 23andMe receives FDA clearance for hereditary colorectal cancer syndrome genetic test. https://​www.​healio.​com/​hematology-oncology/​gastrointestinal​-cancer/​news/​online/​%7Bbdf4ae56-7c9a-4457-a6fa-34c9a9e9e24a%7D/​23andme-receives-fda-clearance-for-hereditary-colorectal-cancer-syndrome-genetic-test. Accessed 1 June 2019
Metadaten
Titel
Characterizing germline APC and MUTYH variants in Ashkenazi Jews compared to other individuals
verfasst von
Chinedu Ukaegbu
Zohar Levi
Tara D. Fehlmann
Hajime Uno
Anu Chittenden
Jennifer A. Inra
Shilpa Grover
Fay Kastrinos
Sapna Syngal
Matthew B. Yurgelun
Publikationsdatum
03.08.2020
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 2/2021
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-020-00198-x

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.